Medicare Enrolled
Dr. Navneet Singh, D.O.
Pulmonary Disease · Santa Ana, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Singh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Singh?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Singh
Dr. Navneet Singh is a pulmonary disease specialist in Santa Ana, CA, with 11 years of NPI registration. Based on federal Medicare data, Dr. Singh performed 3,425 Medicare services across 1,943 unique beneficiaries.
Between the years covered by Open Payments, Dr. Singh received a total of $5,009 from 29 pharmaceutical and/or device companies across 220 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Singh is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 9% volume in CA
$5,009 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,425
Medicare services
Top 9% in CA for pulmonary disease
1,943
Unique beneficiaries
$101
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~311 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,263 | $100 | $200 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
597 | $153 | $250 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
218 | $144 | $375 |
| Spirometry test A test that measures the amount of air you can exhale and how fast you can blow it out. The provider evaluates the results to check lung function. |
155 | $20 | $50 |
| New patient office visit, complex (60-74 min) | 145 | $185 | $275 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
131 | $77 | $200 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
129 | $48 | $120 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
128 | $51 | $140 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
127 | $98 | $201 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
104 | $23 | $80 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
65 | $99 | $385 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
65 | $177 | $427 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
64 | $110 | $200 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
63 | $35 | $110 |
| Sedation by physician, initial 15 minutes Administration of a drug to induce depression of consciousness by the physician performing a procedure. This code covers the initial 15 minutes of sedation for patients aged 5 years or older. |
55 | $10 | $75 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
34 | $12 | $25 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
33 | $43 | $150 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
16 | $3 | $50 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
11 | $29 | $80 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
11 | $64 | $120 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
11 | $63 | $214 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$5,009
Total received (2018-2024)
Avg $716/year across 7 years
Top 27% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
29
Companies
220
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,009 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,696
2023
$2,169
2022
$800
2021
$176
2020
$13
2019
$73
2018
$82
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$248
Regeneron Healthcare Solutions, Inc.
$245
Mylan Specialty L.P.
$186
ABBVIE INC.
$138
Amgen Inc.
$137
Janssen Pharmaceuticals, Inc
$87
AstraZeneca Pharmaceuticals LP
$85
Electromed, Inc.
$76
Vifor Pharma, Inc.
$74
Boehringer Ingelheim Pharmaceuticals, Inc.
$65
Baxter Healthcare
$63
Inari Medical, Inc.
$47
Gilead Sciences, Inc.
$41
GENZYME CORPORATION
$33
United Therapeutics Corporation
$29
Grifols USA, LLC
$29
ANI Pharmaceuticals, Inc.
$29
Takeda Pharmaceuticals U.S.A., Inc.
$26
Actelion Pharmaceuticals US, Inc.
$22
Pulmonx Corporation
$20
ZOLL Respicardia, Inc.
$15
Top 3 companies account for 40.0% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$1,113
Regeneron Healthcare Solutions, Inc.
$710
Boehringer Ingelheim Pharmaceuticals, Inc.
$517
Mylan Specialty L.P.
$439
AstraZeneca Pharmaceuticals LP
$384
Actelion Pharmaceuticals US, Inc.
$226
Janssen Pharmaceuticals, Inc
$205
Baxter Healthcare
$183
Amgen Inc.
$163
ABBVIE INC.
$138
Grifols USA, LLC
$134
GENZYME CORPORATION
$93
Electromed, Inc.
$76
Vifor Pharma, Inc.
$74
United Therapeutics Corporation
$74
Philips Electronics North America Corporation
$72
Merck Sharp & Dohme Corporation
$63
Inari Medical, Inc.
$47
TETRAPHASE PHARMACEUTICALS, INC.
$45
Allergan Inc.
$43
Gilead Sciences, Inc.
$41
ANI Pharmaceuticals, Inc.
$29
Bayer HealthCare Pharmaceuticals Inc.
$28
Takeda Pharmaceuticals U.S.A., Inc.
$26
PFIZER INC.
$26
Pulmonx Corporation
$20
ZOLL Respicardia, Inc.
$15
Inogen, Inc.
$14
Teva Pharmaceuticals USA, Inc.
$11
Top 3 companies account for 46.7% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · AIRSUPRA · AVYCAZ · Adempas · AirDuo Digihaler · BREZTRI · CHARTIS CATHETER · DUPIXENT · ELIQUIS · FASENRA · FLOWTRIEVER CATHETER · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hillrom - Volara System · INOGEN · NUCALA · OFEV · OPSUMIT · PURIFIED CORTROPHIN GEL · Prolastin-C Liquid · S · SMARTVEST · STIOLTO RESPIMAT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · UPTRAVI · XARELTO · Xerava · YUPELRI · Yupelri · ZERBAXA · Zemaira · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
116
Per 100K population
3.7
County median income
$113,702
Nearest hospital
COASTAL COMMUNITIES HOSPITAL
2.1 mi
2.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Singh is a clinical cardiology specialist, with above-average Medicare volume (top 9% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Singh experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Singh performed 1,263 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Singh receive payments from pharmaceutical companies?
Yes. Dr. Singh received a total of $5,009 from 29 companies across 220 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Singh's costs compare to other pulmonary diseases in Santa Ana?
Dr. Singh's average Medicare payment per service is $101. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Singh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Santa Ana
Browse pulmonary diseases in Santa Ana ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology